<DOC>
	<DOCNO>NCT01644474</DOCNO>
	<brief_summary>Alirocumab ( SAR236553/REGN727 ) fully human monoclonal antibody bind PCSK9 ( proprotein convertase subtilisin/kexin type 9 ) . Primary Objective study : To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab comparison ezetimibe 24 week treatment participant hypercholesterolemia . Secondary Objectives : - To evaluate effect alirocumab comparison ezetimibe LDL-C time point - To evaluate effect alirocumab lipid parameter - To evaluate safety tolerability alirocumab</brief_summary>
	<brief_title>Efficacy Safety Alirocumab ( SAR236553/REGN727 ) Versus Ezetimibe Patients With Hypercholesterolemia</brief_title>
	<detailed_description>The maximum study duration 34 week per participant , include 24-week randomized treatment period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Inclusion criterion : Participants hypercholesterolemia Exclusion criterion : Age &lt; 18 legal age adulthood , whichever great LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) &gt; 190 mg/dL ( &gt; 4.9 mmol/L ) Fasting serum triglyceride ( TG ) &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) Known history homozygous heterozygous familial hypercholesterolemia The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>